Isorhamnetin

Isorhamnetin

SCHEMBL29377152

COc1cc(-c2oc3cc(O)cc(O)c3c(=O)c2O)ccc1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 9/20 1.00
KMT2A Q03164 9/20 1.00
CYP1A2 P05177 7/20 1.00
CYP1A1 P04798 6/20 1.00
CYP1B1 Q16678 6/20 1.00
XDH P47989 4/20 1.00
IPMK Q8NFU5 4/20 1.00
IP6K2 Q9UHH9 4/20 1.00
CA12 O43570 3/20 1.00
CA2 P00918 3/20 1.00
PPARG P37231 3/20 1.00
CA7 P43166 3/20 1.00
CA4 P22748 2/20 1.00
ABCB1 P08183 4/20 0.76
NOX4 Q9NPH5 3/20 0.74
FTO Q9C0B1 3/20 0.73
MAOA P21397 2/20 0.73
KDM4E B2RXH2 6/20 0.72
HSD17B10 Q99714 6/20 0.72
MAPT P10636 6/20 0.72

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Isorhamnetin SCHEMBL30385934 1.00 MEN1 (1.00) MEN1KMT2ACYP1A2CYP1A1CYP1B1
Isorhamnetin SCHEMBL19235 1.00 MEN1 (1.00) MEN1KMT2ACYP1A2CYP1A1CYP1B1
Isorhamnetin SCHEMBL29390102 1.00 MEN1 (1.00) MEN1KMT2ACYP1A2CYP1A1CYP1B1
Isorhamnetin SCHEMBL28182051 0.96 MEN1 (0.93) MEN1KMT2ACYP1A2CYP1A1CYP1B1
Isorhamnetin SCHEMBL3715283 0.96 MEN1 (0.93) MEN1KMT2ACYP1A2CYP1A1CYP1B1
SCHEMBL3211188 0.93 MEN1 (0.86) MEN1KMT2ACYP1A2CYP1A1CYP1B1
SCHEMBL29575749 0.93 MEN1 (0.86) MEN1KMT2ACYP1A2CYP1A1CYP1B1
SCHEMBL29442903 0.93 MEN1 (0.86) MEN1KMT2ACYP1A2CYP1A1CYP1B1
SCHEMBL30256517 0.93 MEN1 (0.86) MEN1KMT2ACYP1A2CYP1A1CYP1B1
Rhamnazin SCHEMBL39443 0.91 MEN1 (0.84) MEN1KMT2ACYP1A2CYP1A1CYP1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250351836-A1 SEED EXTRACT FOR USE DURING FOOD COOKING AND STORAGE PROCESSES Khalifa University of Science and Technology (AE) 2025-11-20 US claimed
CN-119019999-A Electric automobile cooling liquid and preparation method thereof 上海德联化工有限公司 2024-11-26 CN claimed
CN-115315195-B Hydroxy-and methoxy-substituted flavonoids and use thereof 弗门尼舍有限公司 2024-07-02 CN claimed
CN-115315195-A Hydroxy-and methoxy-substituted flavonoids and their use 弗门尼舍有限公司 2022-11-08 CN claimed
CN-114040986-A Method of diagnosing disease 4D制药科克有限公司 2022-02-11 CN claimed
US-20250351836-A1 SEED EXTRACT FOR USE DURING FOOD COOKING AND STORAGE PROCESSES Khalifa University of Science and Technology (AE) 2025-11-20 US disclosed
US-20250339399-A1 SUPRAMOLECULAR SELF-ASSEMBLY SYSTEM BEIJING CREATRON INSTITUTE OF PHARMACEUTICAL RES CO LTD (CN) 2025-11-06 US disclosed
CN-119367384-B Application of quercetin derivative Q3MG in preparation of anti-tumor invasion and metastasis drugs 芙蓉实验室 2025-04-08 CN disclosed
WO-2025038482-A2 USE OF FISETIN FOR REDUCING THE INCIDENCE OF ATRIAL FIBRILLATION RHODE ISLAND HOSPITAL (US) 2025-02-20 WO disclosed
US-20250041318-A1 STERILANTS COMPOSITION, KITS AND METHODS OF USE THEREOF COMMUNITREAT LTD. (IL) 2025-02-06 US disclosed
CN-119367384-A Application of quercetin derivative Q3MG in preparation of anti-tumor invasion and metastasis drugs 芙蓉实验室 2025-01-28 CN disclosed
US-20240398715-A1 ORAL SOFT CAPSULE THAT ENCAPSULATES A NALBUPHINE FORMULATION PHYTOHEALTH CORPORATION (TW) 2024-12-05 US disclosed
EP-4210656-A1 SENOLYTIC COMPOUNDS AND COMPOSITIONS Nuchido Limited (GB) 2023-07-19 EP disclosed
WO-2023100184-A1 STERILANTS COMPOSITION, KITS AND METHODS OF USE THEREOF COMMUNITREAT LTD. (IL) 2023-06-08 WO disclosed
CN-116036073-A Application of isorhamnetin in preparation of drugs for inducing nasopharyngeal carcinoma cells to undergo side apoptosis 广东医科大学 2023-05-02 CN disclosed
CN-115315195-A Hydroxy-and methoxy-substituted flavonoids and their use 弗门尼舍有限公司 2022-11-08 CN disclosed
WO-2022189156-A1 HYDROXY- AND METHOXY-SUBSTITUTED FLAVONOIDS AND THEIR USE FIRMENICH SA (CH) 2022-09-15 WO disclosed
CN-114699401-A Application of isorhamnetin in preparation of thoracic aorta vasodilation drugs 宁夏医科大学 2022-07-05 CN disclosed
WO-2022053800-A1 SENOLYTIC COMPOUNDS AND COMPOSITIONS Nuchido Limited (GB) 2022-03-17 WO disclosed
CN-114040986-A Method of diagnosing disease 4D制药科克有限公司 2022-02-11 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250339399-A1 SUPRAMOLECULAR SELF-ASSEMBLY SYSTEM S100A8, TP53, AQP1 MEN1 312/4885KMT2A 4248/4885CYP1A2 4394/4885
US-20240398715-A1 ORAL SOFT CAPSULE THAT ENCAPSULATES A NALBUPHINE FORMULATION TREH, SORD, SYMPK MEN1 1726/4885KMT2A 2209/4885CYP1A2 1633/4885
US-20250041318-A1 STERILANTS COMPOSITION, KITS AND METHODS OF USE THEREOF NASP, ACR, ALPG MEN1 743/4885KMT2A 1588/4885CYP1A2 987/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.